Volume 8, Issue 2 (4-2026)
pbp 2026, 8(2): 256-267 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Esmaeili M. Applications of Nanoplatforms in Helicobacter pylori Infection: A Narrative Review. pbp 2026; 8 (2) :256-267
URL: http://pbp.medilam.ac.ir/article-1-438-en.html
URL: http://pbp.medilam.ac.ir/article-1-438-en.html
1Department of Internal medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , Dr.mahsa.es@gmail.com
Abstract: (152 Views)
Objective: Helicobacter pylori is a spiral-shaped, Gram-negative bacterium that colonises the gastric mucosa and is recognised as the principal aetiological agent of chronic gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma. The increasing prevalence of antibiotic-resistant strains, declining eradication rates associated with conventional treatment regimens, and frequent recurrence of infection have created an urgent need for alternative therapeutic strategies. Nanotechnology-based drug delivery systems have emerged as promising approaches because they can selectively target the gastric mucosa, enhance drug stability, improve penetration into bacterial biofilms, and increase local antimicrobial concentrations while minimising systemic exposure. This review critically examines the therapeutic potential of nanoplatforms for the management of H. pylori infection and discusses their underlying mechanisms of action.
Methods: A comprehensive analytical review was conducted based on a systematic literature search of PubMed, Scopus, and Web of Science for studies published between 2010 and 2025. Medical Subject Headings (MeSH) and related keywords, including Helicobacter pylori, nanoparticles, targeted drug delivery, antibacterial therapy, and biofilm, were used to identify relevant publications. Eligible studies included in vitro investigations, in vivo animal studies, and relevant review articles. The retrieved evidence was synthesised using qualitative thematic analysis.
Results: The available evidence indicates that nanotechnology-based platforms offer multiple complementary strategies for combating H. pylori. Metallic nanoparticles, particularly silver, gold, and zinc-based nanomaterials, together with polymeric–lipid nanocarriers and chitosan-based delivery systems, demonstrated potent antibacterial activity through disruption of the bacterial cell envelope, generation of reactive oxygen species (ROS), inhibition of urease activity, and interference with biofilm formation. In addition, mucoadhesive and targeted nanoformulations encapsulating therapeutic agents such as berberine and clarithromycin enhanced gastric mucosal retention, enabled sustained drug release, increased local drug concentrations, and consequently reduced bacterial colonisation, attenuated gastric inflammation, and promoted mucosal healing. Collectively, these findings suggest that nanomedicine may represent an effective strategy for overcoming antibiotic resistance and improving eradication outcomes. Nevertheless, concerns regarding nanoparticle-associated toxicity, tissue accumulation, manufacturing scalability, and long-term biosafety remain important challenges that require further investigation.
Conclusion: Nanoparticle-based drug delivery systems represent a promising therapeutic strategy for the management of H. pylori infection by enhancing antibiotic penetration, disrupting bacterial biofilms, improving targeted drug delivery, and exerting direct antibacterial effects. Although preclinical findings are highly encouraging, successful clinical translation will require rigorous safety evaluation, standardised formulation strategies, and well-designed clinical trials to establish long-term efficacy and biosafety.
Methods: A comprehensive analytical review was conducted based on a systematic literature search of PubMed, Scopus, and Web of Science for studies published between 2010 and 2025. Medical Subject Headings (MeSH) and related keywords, including Helicobacter pylori, nanoparticles, targeted drug delivery, antibacterial therapy, and biofilm, were used to identify relevant publications. Eligible studies included in vitro investigations, in vivo animal studies, and relevant review articles. The retrieved evidence was synthesised using qualitative thematic analysis.
Results: The available evidence indicates that nanotechnology-based platforms offer multiple complementary strategies for combating H. pylori. Metallic nanoparticles, particularly silver, gold, and zinc-based nanomaterials, together with polymeric–lipid nanocarriers and chitosan-based delivery systems, demonstrated potent antibacterial activity through disruption of the bacterial cell envelope, generation of reactive oxygen species (ROS), inhibition of urease activity, and interference with biofilm formation. In addition, mucoadhesive and targeted nanoformulations encapsulating therapeutic agents such as berberine and clarithromycin enhanced gastric mucosal retention, enabled sustained drug release, increased local drug concentrations, and consequently reduced bacterial colonisation, attenuated gastric inflammation, and promoted mucosal healing. Collectively, these findings suggest that nanomedicine may represent an effective strategy for overcoming antibiotic resistance and improving eradication outcomes. Nevertheless, concerns regarding nanoparticle-associated toxicity, tissue accumulation, manufacturing scalability, and long-term biosafety remain important challenges that require further investigation.
Conclusion: Nanoparticle-based drug delivery systems represent a promising therapeutic strategy for the management of H. pylori infection by enhancing antibiotic penetration, disrupting bacterial biofilms, improving targeted drug delivery, and exerting direct antibacterial effects. Although preclinical findings are highly encouraging, successful clinical translation will require rigorous safety evaluation, standardised formulation strategies, and well-designed clinical trials to establish long-term efficacy and biosafety.
Type of Study: Review/Systemtic review |
Subject:
Biotechnology
Received: 2025/09/3 | Accepted: 2026/04/16 | Published: 2026/04/20
Received: 2025/09/3 | Accepted: 2026/04/16 | Published: 2026/04/20
References
1. Malfertheiner P, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19.
2. Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158-1165.
3. Goodwin CS, Mendall MM, Northfield TC. Helicobacter pylori infection. Lancet. 1997;349(9047):265-269.
4. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449-490.
5. Backert S, Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2011;16 Suppl 1:19-25.
6. Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017;22 Suppl 1:e12405.
7. Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21(2):315-324.
8. Van der Hulst RWM, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996;1(1):6-19.
9. Bytzer P, O’Morain C. Treatment of Helicobacter pylori. Helicobacter. 2005;10 Suppl 1:40-46.
10. Shiri S, Alizadeh K, Abbasi N. A novel technique for simultaneous determination of drugs using magnetic nanoparticles-based dispersive micro-solid-phase extraction in biological fluids and wastewaters. MethodsX. 2020;7:101040. doi:10.1016/j.mex.2020.100952
11. Mansour RM, et al. The role of miRNAs in pathogenesis, diagnosis, and therapy of Helicobacter pylori infection, gastric cancer-causing bacteria: special highlights on nanotechnology-based therapy. Microb Pathog. 2025;205:107646.
12. Garg A, Karhana S, Khan MA. Nanomedicine for the eradication of Helicobacter pylori: recent advances, challenges and future perspective. Future Microbiol. 2024;19(5):431-447.
13. Khan TU, et al. Advanced nano-delivery systems in H. pylori eradication: targeting, efficacy, and clinical translation. Expert Opin Drug Deliv. 2026;23(1):61-81.
14. Adib ZA, et al. A smart nanopaper sensor for optical diagnosis of Helicobacter pylori infection. Mater Adv. 2023;4(20):4965-4974.
15. Jiang J, et al. Rapid, economical detection of Helicobacter pylori using gold colloidal nanoparticle biosensors. ACS Omega. 2025;10(7):6559-6566.
16. Garg A, Karhana S, Khan MA. Nanomedicine for the eradication of Helicobacter pylori: recent advances, challenges and future perspective. Future Microbiol. 2024;19(5):431-447.
17. Khan S, et al. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther. 2022;20(3):407-424.
18. Yin X, Zhang Y, Wang X, Li Y, Chen H, Liu J, et al. Metal-based nanoparticles: a prospective strategy for Helicobacter pylori treatment. Int J Nanomedicine. 2023;18:2413-2429.
19. Zhang XL, Jiang AM, Ma ZY, Li XB, Xiong YY, Dou JF, et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit anti-Helicobacter pylori activity in vitro and in vivo. Molecules. 2015;20(3):3972-3985.
20. Zou Y, Chen X, Sun Y, Li P, Xu M, Fang P, et al. Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria. J Control Release. 2022;348:370-385.
21. Cai J, Huang H, Song W, Hu H, Chen J, Zhang L, et al. Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int J Pharm. 2015;495(2):728-737.
22. Elmehbad NY, Mohamed NA, Abd El-Ghany NA, Abdel-Aziz MM. Evaluation of the in vitro anti-inflammatory and anti-Helicobacter pylori activities of chitosan-based biomaterials modified with copper oxide nanoparticles. Int J Biol Macromol. 2023;253:127277.
23. Li P, Chen X, Shen Y, Li H, Zou Y, Yuan G, et al. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019;300:52-63.
24. Lin YH, Lin JH, Chou SC, Chang SJ, Chung CC, Chen YS, et al. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study. Nanomedicine. 2015;10(1):57-71.
25. Angsantikul P, Thamphiwatana S, Zhang Q, Spiekermann K, Zhuang J, Fang RH, et al. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv Ther. 2018;1(2):1800016.
26. Shehab WS, Elsayed DA, Abdel Hamid AM, Assy MG, Mouneir SM, Hamed EO, et al. CuO nanoparticles for green synthesis of significant anti-Helicobacter pylori compounds with in silico studies. Sci Rep. 2024;14(1):1608.
27. Yahya R, Al-Rajhi AM, Alzaid SZ, Al Abboud MA, Almuhayawi MS, Al Jaouni SK, et al. Molecular docking and efficacy of Aloe vera gel based on chitosan nanoparticles against Helicobacter pylori and its antioxidant and anti-inflammatory activities. Polymers (Basel). 2022;14(15):2994.
28. Kamankesh M, et al. Future nanotechnology-based strategies for improved management of Helicobacter pylori infection. Small. 2024;20(3):2302532.
29. Gupta A, et al. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. Heliyon. 2023;9(10).
30. Gupta A, et al. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. Heliyon. 2023;9(10).
31. Asgari S, Nikkam N, Saniee P. Metallic nanoparticles as promising tools to eradicate H. pylori: a comprehensive review on recent advancements. Talanta Open. 2022;6:100129.
32. Safarov T, et al. An overview of nanotechnology-based treatment approaches against Helicobacter pylori. Expert Rev Anti Infect Ther. 2019;17(10):829-840.
33. Yonezawa H, Osaki T, Kamiya S. Biofilm formation by Helicobacter pylori and its involvement for antibiotic resistance. Biomed Res Int. 2015;2015:914791.
34. Jawed Khan MJ, Hafeez A, Aftab Siddiqui M. Nanocarrier based delivery of berberine: a critical review on pharmaceutical and preclinical characteristics of the bioactive. Curr Pharm Biotechnol. 2023;24(11):1449-1464.
35. Lin Y, et al. Recent advances in nano-formulations for skin wound repair applications. Drug Des Devel Ther. 2022;16:2707-2728.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |